Sign in
CompletedNo phase

Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry

Key facts

Who runs it
Central Hospital, Nancy, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
25 people enrolled
Started
1 Nov 2024
Ended
28 Feb 2025
Type of study
Observational
Treatments tested
  • scintigraphy of 177Lu-DOTATATE
Record updated
4 March 2025

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Patients treated with 177Lu-DOTATATE for meningioma at Nancy University Hospital
  • Patients with neuroendocrine tumors in the EVADOV study who underwent scintigraphy on D1, D4 and D7 (± 1 day)

Who cannot take part

  • Patients who refused to have their data used retrospectively

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study was to compare a semi-automatic segmentation method with manual reference segmentation to determine an overall tumor volume on post-therapy scintigraphy at D1 in patients treated with 177Lu-DOTATATE for meningioma or neuroendocrine tumor for dosimetric calculation.

The group in the trial

  • Patients treated with 177Lu-DOTATATE

    Patients treated with 177Lu-DOTATATE for a meningioma at the Nancy University Hospital and for a neuroencrine tumor in the EVADOVE study NCT04467567 (who underwent scintigraphy on D1, D4 and D7 (± 1 day)

    Treatment: scintigraphy of 177Lu-DOTATATE

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 March 2025